Shree Ganesh Biotech India Hits 52-Week Low at Rs.0.65 Amidst Continued Downtrend

On 20 Nov 2025, Shree Ganesh Biotech India’s share price touched Rs.0.65, the lowest level recorded in the past year and also its all-time low. This price point reflects a continued slide, with the stock losing value for three consecutive days, resulting in a cumulative return of -4.29% over this period. The day’s performance showed a decline of 1.47%, underperforming the Pharmaceuticals & Biotechnology sector by 1.51%.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish momentum. This contrasts with the broader market, where the Sensex opened higher at 85,470.92 points, gaining 284.45 points or 0.33%, and was trading near its 52-week high of 85,290.06 points. The Sensex’s 50-day moving average remains above its 200-day moving average, signalling a generally bullish trend for large-cap stocks, which have been leading the market gains.

Over the past year, Shree Ganesh Biotech India’s stock has recorded a return of -37.38%, a stark contrast to the Sensex’s positive return of 9.94% during the same period. The stock’s 52-week high was Rs.1.19, indicating a significant reduction in market value over the last twelve months. This decline has occurred despite the broader market’s upward trajectory, highlighting company-specific factors influencing the stock’s performance.

Financially, the company’s recent results reveal several areas of concern. Net sales for the nine-month period stood at Rs.5.16 crores, reflecting a contraction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) for the same period was negative Rs.0.61 crores, also showing a decline of 44.64%. These figures suggest a challenging revenue environment and continued losses.

Further, the company’s debt servicing capacity appears constrained, with an average EBIT to interest ratio of 0.91, indicating that earnings before interest and tax are insufficient to comfortably cover interest expenses. The return on equity (ROE) averaged 2.62%, signalling limited profitability relative to shareholders’ funds. Additionally, the debtors turnover ratio for the half-year period was recorded at 0.00 times, pointing to potential inefficiencies in receivables management.

Profitability metrics also highlight risks, with the company reporting negative EBITDA levels. Over the past year, profits have fallen by approximately 86.6%, underscoring the financial pressures faced by the business. The stock’s valuation appears elevated relative to its historical averages, contributing to its classification as a higher-risk security within its sector.

Ownership of Shree Ganesh Biotech India is predominantly held by non-institutional shareholders, which may influence liquidity and trading dynamics. The company operates within the Pharmaceuticals & Biotechnology sector, a space that has generally seen mixed performance depending on individual company fundamentals and market conditions.

In summary, Shree Ganesh Biotech India’s stock has reached a critical low point at Rs.0.65, reflecting a combination of subdued financial results, weak profitability indicators, and a challenging market environment for the company. While the broader market and sector indices have shown resilience, the stock’s performance remains subdued, with key metrics signalling ongoing difficulties in revenue generation and debt management.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →